HeartWare HVAD: Risk Factors for Adverse Outcomes
Mark S. Slaughter, MD Professor and Chair
Department Cardiovascular and Thoracic Surgery University of Louisville
Disclosures
• HeartWare, Inc: research grant support • Cormatrix: research grant support • Carmat: scientific advisory board • APK: research grant support
HVAD ADVANCE Bridge to Transplantation Study Design
• Objective: To evaluate safety & efficacy of the HeartWare HVAD® in patients listed for cardiac transplantation
• Multi-center, prospective, non-randomized, two arm study – HVAD (N=140) vs. Control (INTERMACS™, N=499)
• Primary endpoint: Non-inferiority to control
• First BTT using contemporaneous VAD patients as control arm (INTERMACS™ registry)
• Primary Endpoint: – Success at 180 days – alive on original device, transplanted, or explanted for recovery (alive
60 days post removal) – Kaplan-Meier Survival at 180 days
• 4 CAP Installments included (Total N=242)
Aaronson, et al. Circulation. 2012;125(25):3191-200 Slaughter, et al. J Heart Lung Transpl. 2013; 32: 675-683
Patient Demographics
Baseline Characteristic BTT and CAP
(N = 382) BTT
(N = 140) CAP
(N = 242)
Age (years) 53.2 ± 11.7 53.3 ± 10.3 53.1 ± 12.5
Male sex (%) 71.2% 72.1% 70.7%
Race (%) White Black/African American Hispanic/Other
68.1% 26.4% 5.5%
72.1% 22.9% 5.0%
65.7% 28.5% 5.8%
Body-mass index (kg/m2) 28. 2 ± 6.1 28.5 ± 6.0 28.0 ± 6.1
Body surface area (m2) 2.0 ± 0.3 2.1 ± 0.3 2.0 ± 0.3
Ischemic cause of heart failure (%) 38.0% 40.7% 36.4%
Left ventricular ejection fraction (%) 17.3 ± 7.3 18.0 ± 7.1 16.9 ± 7.3
Patient Demographics (continued)
Baseline Characteristic BTT and CAP
(N = 382) BTT
(N = 140) CAP
(N = 242)
Pulmonary artery pressure (mmHg)
Systolic Diastolic
48.8 ± 14.5 24.1 + 8.4
51.0 ± 15.1 25.6 + 8.9
48.1 ± 14.3 23.6 ± 8.2
Arterial blood pressure (mmHg)
Systolic Diastolic Mean
103.2 ± 15.3 63.5 ± 10.6 77.5 ± 11.0
103.3 ± 15.6 63.7 ± 11.2 76.2 ± 12.1
103.7 ± 15.2 63.4 ± 10.3 78.1 ± 10.4
Cardiac index (liters/min/m2)
2.2 ± 0.6 2.1 ± 0.6 2.2 ± 0.6
NYHA Class (%)
II III IV
0.5 3.4
95.8
0.7 3.6
95.0
0.4 3.3
96.3
INTERMACS (%)
1 2 3
4-7
5.5 34.8 40.6 19.1
5.0 27.9 42.9 24.3
5.8 38.8 39.3 16.1
Kaplan Meier Survival in HVAD BTT+CAP Clinical Trial
90% 84%
Days
Even
t Fre
e R
ate
Month 0 2 4 6 8 10 12 18 24 Patient at risk 382 356 305 261 218 191 165 114 74
Survival 100% 97% 94% 90% 89% 86% 84% 79% 71%
71% 79%
Success Outcomes (N=382)
Endpoint Outcome at 6 months
Success Transplanted or Myocardial Recovery or Alive on original device
87.6%
Alive on original device 66.5%
Transplanted 20.8%
Myocardial Recovery 0.3%
Died 8.2%
Exchanged 4.2%
Mean duration of support (incl. post exchange) = 423 days
Adverse Events in BTT+CAP (N=382) N=382 with 406.6 Patient-Years of Support
Complication Patients with event, n (%)
Number of Events
Event Rate
Ventricular Arrhythmia 77 (20.2) 101 0.25
Gastrointestinal Bleeding 59 (15.4) 108 0.27
Right Heart Failure (RHF) 129 (33.8) 149 0.37
RHF Requiring RVAD 15 (3.9) 15 0.04
Ischemic Stroke 26 (6.8) 31 0.08
Hemorrhagic Stroke 32 (8.4) 34 0.08
Device Exchange for Suspected Thrombus
16 (4.2) 17 0.04
Driveline Infection 75 (19.6) 102 0.25
Sepsis 72 (18.8) 92 0.23
Renal Failure 39 (10.2) 46 0.11
Freedom from Thrombus Events
Freedom from any thrombus event: 6 months = 96%; 1 year = 92%
Freedom from exchange for thrombus: 6 months = 98%; 1 year = 95.4%
Time to any thrombus event
Time to exchange for thrombus
Najjar, et al. J Heart Lung Transpl. 2014; 33: 23-34 (e-pub ahead of print 13 Dec 2013)
Multivariate Risk Factors for VAD Thrombus
Najjar, et al. J Heart Lung Transpl. 2014; 33: 23-34 (e-pub ahead of print 13 Dec 2013)
Freedom from CVA
ICVA
HCVA
Freedom from any ICVA: 6 months = 96%; 1 year = 93%; 2 years = 88%
Freedom from HCVA: 6 months = 95%; 1 year = 90%; 2 years = 86%
Manuscript in preparation (Teuteberg, et al.)
Infections in BTT+CAP • 84% driveline infections were successfully managed with antibiotics
• Driveline infections had no adverse impact on survival
• 3.5% of patients with sepsis had a device exchange for VAD thrombus within 1 - 4 days of a sepsis diagnosis.
• 16% of sepsis events were either concurrent with or were preceded (within 10 days) by a urinary tract infection (UTI) with positive urine cultures.
• 17.5% of patients with sepsis died due to sepsis-related events such as neurological events and multisystem organ failure.
• 14% of all sepsis events were associated with a stroke event (stroke within -1 to 6 days of sepsis). Of patients with a stroke and sepsis, 70% subsequently died due to sepsis-related neurological events and associated multisystem organ failure.
• Manuscript recently accepted by JHLT in April 2014 (John, et al.)
Gastrointestinal Bleeding in BTT+CAP • 15.9% (59/382) patients experienced a GI bleed. Overall, the
59 patients had 108 bleeding events that resulted in 0.27 EPPY (range 1-7 events) with 2/3 experiencing a recurrent GIB.
• Most GI bleeds (>86%) occurred >30 days post implant.
• Despite interruptions in anticoagulation in 2/3 of patients with GI bleeds, only 8.5% had any subsequent thrombotic events.
• The most common etiology of GI bleeding was arteriovenous malformations
• There were no deaths directly related to GI bleeding, and no difference in overall survival between patients with and without GI bleeding events.
• Manuscript in preparation (Goldstein, et al).
Conclusions
• ADVANCE/CAP trial met study end points • Adverse event profile may vary between axial vs.
centrifugal pumps • New patient/device management strategies may
reduce HVAD related adverse events
Top Related